285 related articles for article (PubMed ID: 15717992)
1. Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.
Vaidya AP; Parnes AD; Seiden MV
Curr Treat Options Oncol; 2005 Mar; 6(2):103-14. PubMed ID: 15717992
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate and its potential implications for gynecologic cancers.
Dushkin H; Schilder RJ
Curr Treat Options Oncol; 2005 Mar; 6(2):115-20. PubMed ID: 15717993
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies for gynecologic malignancies.
Hyde J; McMeekin DS
Curr Treat Options Oncol; 2005 Mar; 6(2):121-32. PubMed ID: 15717994
[TBL] [Abstract][Full Text] [Related]
4. The Epigenetic Landscape in the Treatment of Gynecologic Malignancies.
Eskander RN
Am Soc Clin Oncol Educ Book; 2018 May; 38():480-487. PubMed ID: 30231335
[TBL] [Abstract][Full Text] [Related]
5. Overview of clinical trials with epidermal growth factor receptor inhibitors in advanced non-small cell lung cancer.
Thomas M
Semin Oncol Nurs; 2002 Nov; 18(4 Suppl 4):20-7. PubMed ID: 12534150
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.
Reyes HD; Thiel KW; Carlson MJ; Meng X; Yang S; Stephan JM; Leslie KK
Mol Diagn Ther; 2014 Apr; 18(2):137-51. PubMed ID: 24403167
[TBL] [Abstract][Full Text] [Related]
7. Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies.
Markman M
Womens Health (Lond); 2016 Jul; 12(4):396-9. PubMed ID: 27638892
[TBL] [Abstract][Full Text] [Related]
8. Laparoscopy and oncology: where do we stand today?
Theodoridis TD; Bontis JN
Ann N Y Acad Sci; 2003 Nov; 997():282-91. PubMed ID: 14644836
[TBL] [Abstract][Full Text] [Related]
9. Taxanes in the management of gynecologic malignancies.
Markman M
Expert Rev Anticancer Ther; 2008 Feb; 8(2):219-26. PubMed ID: 18279063
[TBL] [Abstract][Full Text] [Related]
10. Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.
Tinker AV; Hirte HW; Provencher D; Butler M; Ritter H; Tu D; Azim HA; Paralejas P; Grenier N; Hahn SA; Ramsahai J; Seymour L
Clin Cancer Res; 2019 Oct; 25(20):6052-6060. PubMed ID: 31308062
[TBL] [Abstract][Full Text] [Related]
11. Laparoscopy in gynecologic malignancies.
Chi DS
Oncology (Williston Park); 1999 Jun; 13(6):773-82; discussion 782-5 passim. PubMed ID: 10378217
[TBL] [Abstract][Full Text] [Related]
12. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
13. Relationship between epidermal growth factor receptor and other prognostic factors in gynecological cancers.
Melpignano M; Vadora E; Debiasi D; Merisio C; Piombo S; Brusati M; Catozzi L; Giovannini G; Piffanelli A; Merialdi A
Acta Biomed Ateneo Parmense; 1993; 64(5-6):227-34. PubMed ID: 7992560
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.
Husseinzadeh N; Husseinzadeh HD
Gynecol Oncol; 2014 May; 133(2):375-81. PubMed ID: 24556063
[TBL] [Abstract][Full Text] [Related]
15. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
16. Staging of gynecologic malignancies.
Ascher SM; Takahama J; Jha RC
Top Magn Reson Imaging; 2001 Apr; 12(2):105-29. PubMed ID: 11296804
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of peritoneal washing cytology in gynecologic malignancies: a controversial issue.
Binesh F; Akhavan A; Behniafard N; Zabihi S; Hosseinizadeh E
Asian Pac J Cancer Prev; 2014; 15(21):9405-10. PubMed ID: 25422232
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases.
Baguley BC; Marshall ES; Holdaway KM; Rewcastle GW; Denny WA
Eur J Cancer; 1998 Jun; 34(7):1086-90. PubMed ID: 9849459
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy in gynecologic cancers: Ready for prime time?
Seoud M; Lundqvist EÅ; Fujiwara K
Int J Gynaecol Obstet; 2015 Oct; 131 Suppl 2():S150-2. PubMed ID: 26433672
[No Abstract] [Full Text] [Related]
20. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Silvestri GA; Rivera MP
Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
